Behavioural Intervention
Exergaming for Spinal Muscular Atrophy
Recruiting1 award4 criteria
Calgary, Alberta
This trial will test if playing video games at home for 8 weeks can help children and youth with spinal muscular atrophy feel more satisfied with their daily activities compared to their usual care.
Spinal Cord Stimulation
Spinal Cord Stimulation for Spinal Muscular Atrophy
Recruiting1 award3 criteria
Pittsburgh, Pennsylvania
This trial tests if spinal cord stimulation (SCS) can improve leg movement in people with Type 3 or 4 Spinal Muscular Atrophy (SMA) who can stand but have motor deficits. SCS uses electrical pulses to help the spinal cord communicate better with the brain, potentially improving muscle control and strength. Spinal cord stimulation (SCS) has been shown to improve motor performance in various conditions, including certain types of muscle weakness.
SMN2 Splicing Modifier
Long-Term Risdiplam for Spinal Muscular Atrophy
Recruiting3 awardsPhase 4
Atlanta, Georgia
This trial will study the long-term safety and effectiveness of the drug risdiplam in patients with spinal muscular atrophy. The trial will last for up to 5 years, and patients will be followed even if they discontinue the drug.
Virus Therapy
Gene Therapy for Spinal Muscular Atrophy
Recruiting1 awardPhase 1 & 2
Columbus, Ohio
This trial uses a harmless virus to deliver a healthy gene directly into the spinal fluid of patients with diseases caused by IGHMBP2 gene defects. The virus helps correct the genetic issues by bringing the healthy gene to the affected cells. This approach has been shown to improve conditions in similar diseases in animals.
Behavioural Intervention
Neurosleeve for Arm Weakness/Paralysis
Recruiting1 award11 criteria
Philadelphia, Pennsylvania
This trial is testing the NuroSleeve, a wearable device that helps people with weak or paralyzed arms move them using electrical signals. It is aimed at those who haven't fully recovered with standard therapies. The device detects small muscle movements and uses them to activate the brace and stimulate muscles, helping with arm movement. Electrical stimulation has been explored in various contexts, including improving arm and hand function in individuals with spinal cord injuries and post-stroke patients.
Popular Filters
Trials for SMA Patients
Monoclonal Antibodies
Long-Term Apitegromab for Spinal Muscular Atrophy
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing a medication called Apitegromab to see if it is safe and effective for people with certain types of spinal muscular atrophy (SMA). It focuses on patients who have already participated in previous research. The goal is to see if the medication can help improve their muscle function over time.
Trials for SMN1 Positive Patients
SMN2 Splicing Modifier
Risdiplam for Presymptomatic Spinal Muscular Atrophy
Recruiting1 awardPhase 2
Orlando, Florida
This trial is testing a medicine called risdiplam, which is taken by mouth. It aims to help infants who have a genetic diagnosis of spinal muscular atrophy (SMA) but are not yet showing symptoms. The medicine works by helping the body make more of a protein that muscles need to stay healthy. The goal is to see if early treatment can prevent or lessen the severity of SMA.
Trials for SMN2 Positive Patients
Antisense Oligonucleotide
Nusinersen for SMA
Recruiting3 awardsPhase 4
Little Rock, Arkansas
This trial is evaluating nusinersen as a treatment for SMA in patients who have previously received onasemnogene abeparvovec. The objectives are to assess the safety and efficacy of nusinersen in this population.
Small Molecule
Risdiplam for Spinal Muscular Atrophy
Recruiting3 awardsPhase 4
Strasburg, Pennsylvania
This trial is for SMA patients who have been treated with nusinersen and are now crossover to 36 months of risdiplam monotherapy. The trial will track the most informative outcomes from the nusinersen trial, while adding the Box and Block Test as an additional measure of upper limb endurance and function.
Phase 3 Trials
Monoclonal Antibodies
Long-Term Apitegromab for Spinal Muscular Atrophy
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing a medication called Apitegromab to see if it is safe and effective for people with certain types of spinal muscular atrophy (SMA). It focuses on patients who have already participated in previous research. The goal is to see if the medication can help improve their muscle function over time.
Antisense Oligonucleotide
Nusinersen for Spinal Muscular Atrophy
Recruiting2 awardsPhase 3
Sacramento, California
This trial is for participants with Spinal Muscular Atrophy who have previously participated in another study. They will be given nusinersen, which is a drug meant to help with the disease. The study is to see if the drug is safe and effective long-term.
Taldefgrobep Alfa for Spinal Muscular Atrophy
Recruiting1 awardPhase 3
Atlanta, Georgia
This trial will test if taldefgrobep alfa can help people with SMA who are already on other treatments. The drug works by blocking a protein that stops muscle growth, potentially making muscles stronger and improving movement. Taldefgrobep alfa has shown promise in increasing muscle mass and function in SMA patients.
Small Molecule
RO7204239 + Risdiplam for Spinal Muscular Atrophy
Recruiting0 awardsPhase 2 & 3
Boston, Massachusetts
This trial tests the safety and effectiveness of combining two treatments, RO7204239 and risdiplam, for patients with spinal muscular atrophy (SMA). Risdiplam helps the body produce a protein needed for muscle movement, while RO7204239 allows muscles to grow bigger and stronger. The study includes SMA patients to see if this combination improves their muscle function and overall health.
Gene Therapy
OAV101 for Spinal Muscular Atrophy
Recruiting1 awardPhase 3
Norfolk, Virginia
This trial is testing a new treatment for people with a severe form of spinal muscular atrophy. The treatment will be given directly into the spinal fluid and will be evaluated for safety, effectiveness, and side effects over 15 months.
Trials With No Placebo
Monoclonal Antibodies
Long-Term Apitegromab for Spinal Muscular Atrophy
Recruiting2 awardsPhase 3
Phoenix, Arizona
This trial is testing a medication called Apitegromab to see if it is safe and effective for people with certain types of spinal muscular atrophy (SMA). It focuses on patients who have already participated in previous research. The goal is to see if the medication can help improve their muscle function over time.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.